JPM vs STRO · P/E 14, rev $182.45B vs rev $62.0M
JPMorgan Chase & Co (JPM) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
JPMorgan Chase & Co (JPM) is a banks - diversified company listed on US. It is led by Jamie Dimon.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported JPM revenue for 2025-12-31 was $182.45B. Net income was $57.05B. Revenue was up 2.8% from 2024-12-31 to 2025-12-31. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
JPM currently screens at market cap $805.69B and trailing P/E 14.2. STRO currently screens at market cap $470.8M.
Not investment advice. Open the JPM and STRO stock pages for the full models.
Not investment advice.